Shots:

• Quanterix to get a non-exclusive license globally to Lilly’s P-tau217 Ab technology for research use including products, services & in vitro diagnostic applications. Lilly will be responsible to fund $11M of development with the Quanterix Accelerator group in 2022
• The collaboration will combine Lilly’s P-tau217 and Quanterix’ Simoa technologies to develop plasma-based biomarkers & provide assess to treatment for patients with AD
• In P-II (TRAILBLAZER-ALZ) study, the therapy showed a reduction in plasma levels of phosphorylated tau protein after treatment with donanemab for AD. The companies also collaborated for future projects focused on the development of Simoa immunoassays

Ref: Businesswire | Image: Businesswire